Pricing & Access· August 17, 2026 · 25 min read
Medicaid's September 10 Deadline: The Coverage Trade for GENEROUS Pricing
By Ran Chen#Medicaid#Drug Pricing#Payer Policy
Topic
Payer Policy
Medicare, commercial payer, PBM, and formulary-policy moves that shape launch curves and gross-to-net.
Pricing & Access· August 17, 2026 · 25 min read
Tavneos on Formularies as FDA Moves to Withdraw: The Coverage Dilemma
Specialty· August 16, 2026 · 17 min read
Leqembi IQLIK Launches: Subcutaneous Lecanemab Moves to Specialty Pharmacy
Policy· August 16, 2026 · 15 min read
Ten PBMs Commit to TrumpRx Cash Prices in Real-Time Tools: The Policy Ledger
By Ran Chen#PBM#Payer Policy#Formulary Strategy
Approvals· August 10, 2026 · 14 min read
177Lu-Edotreotide (ITM-11) for GEP-NET: COMPETE Phase 3 Data and Lutathera Access
By Ran Chen#Radiolabeled Therapy#Oncology#FDA Approval
Specialty· August 10, 2026 · 19 min read
Dermatomyositis Treatment Access (2026): Brepocitinib, Octagam IVIG, and DMARDs
Specialty· August 10, 2026 · 16 min read
Rheumatoid Arthritis Treatment Access (2026): Methotrexate, Biosimilars, and JAKs
Policy· August 9, 2026 · 18 min read
340B Rebate-Model Ruling: D.C. Circuit Puts HHS in the Driver's Seat (2026)
By Ran Chen#340B#Drug Pricing#Payer Policy
Biosimilars· August 7, 2026 · 14 min read
Osteoporosis access landscape: Prolia's 10 denosumab biosimilars and Evenity
By Ran Chen#Biosimilars#Purple Book#Payer Policy
Policy· July 29, 2026 · 25 min read